B6.129P2-Brca2tm2Mak/Cnbc

Status

Available to order

EMMA IDEM:06747
International strain nameB6.129P2-Brca2tm2Mak/Cnbc
Alternative nameBrCa2
Strain typeTargeted Mutant Strains : Conditional mutation
Allele/Transgene symbolBrca2tm2Mak,
Gene/Transgene symbolBrca2

Information from provider

ProviderTak W Mak
Provider affiliationMak Lab, Campbell Family Breast Cancer reseach Institute
Genetic informationConditional targeted mutation of exons 9 and 10 flanked by loxP sites.
Phenotypic informationBrca2-null mice have a defect in embryonic cellular proliferation and die in utero. tBrca2/ T cells were more likely than wild-type cells to undergo spontaneous apoptosis, but apoptosed normally in response to restimulation or DNA-damaging stress signals.
Breeding historyBackcrossed 10 times to C57BL/6.
References
  • Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis.;Cheung Alison M Y, Hande M Prakash, Jalali Farid, Tsao Ming-Sound, Skinnider Brian, Hirao Atsushi, McPherson J Peter, Karaskova Jana, Suzuki Akira, Wakeham Andrew, You-Ten Annick, Elia Andrew, Squire Jeremy, Bristow Rob, Hakem Razqallah, Mak Tak W, ;2002;Cancer research;62;6194-204; 12414647
  • Brca2 deficiency does not impair mammary epithelium development but promotes mammary adenocarcinoma formation in p53(+/-) mutant mice.;Cheung Alison M Y, Elia Andrew, Tsao Ming-Sound, Done Susan, Wagner Kay-Uwe, Hennighausen Lothar, Hakem Razqallah, Mak Tak W, ;2004;Cancer research;64;1959-65; 15026330
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreCNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain
Animals used for archivinghomozygous C57BL/6J, wild-type C57BL/6J
Stage of embryos2-cell

Disease and phenotype information

Orphanet associated rare diseases, based on orthologous gene matching

Literature references

  • Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis.;Cheung Alison M Y, Hande M Prakash, Jalali Farid, Tsao Ming-Sound, Skinnider Brian, Hirao Atsushi, McPherson J Peter, Karaskova Jana, Suzuki Akira, Wakeham Andrew, You-Ten Annick, Elia Andrew, Squire Jeremy, Bristow Rob, Hakem Razqallah, Mak Tak W, ;2002;Cancer research;62;6194-204; 12414647
  • Brca2 deficiency does not impair mammary epithelium development but promotes mammary adenocarcinoma formation in p53(+/-) mutant mice.;Cheung Alison M Y, Elia Andrew, Tsao Ming-Sound, Done Susan, Wagner Kay-Uwe, Hennighausen Lothar, Hakem Razqallah, Mak Tak W, ;2004;Cancer research;64;1959-65; 15026330

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).